// App-Quantinova.ai

2663 : Phase II Study Of Combination Of Hyper-CVAD With Ponatinib In Front Line Therapy Of Patients (pts) With Philadelphia Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL)

Researchers

Presenter

  • Elias Jabbour

Principal Investigators

  • Hagop Kantarjian

  • Deborah A. Thomas

  • Gautam Borthakur

  • William G. Wierda

  • Susan -Brien

  • Farhad Ravandi

  • Jorge Cortes

  • Stefan H. Faderl

  • Naveen Pemmaraju

  • Tapan M. Kadia

  • Rebecca Garris

  • Prescott Hillary

  • Guillermo Garcia-Manero

Medical Centers

  • Department of Bioinformatics, The University of Texas MD Anderson Cancer Center, Houston, TX

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Genetic Disorder

Disease

  • Acute lymphoblastic leukemia

  • Myocardial infarction

  • Heart muscle disease

  • Pancreatitis

  • Venous thrombosis

  • Sepsis

  • Hypercarotenemia and vitamin A deficiency

Biomarkers

  • B-lymphocyte antigen CD20

  • Breakpoint Cluster Region

  • Cluster of Differentiation 206

  • White Blood Cell

Drug/Treatment

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Methotrexate

  • Vincristine

  • Doxorubicin

  • Cytarabine liposomal

  • Prednisone

  • Ponatinib

  • Rituximab

  • dasatinib

  • Imatinib

  • IkT001

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved